![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-m.jpg)
![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-d.jpg)
Filing
SAVARA, INC.
1717 Langhorne Newtown Road, Suite 303
Langhorne, PA 19047
May 20, 2024
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC, 20549
Re: | Savara, Inc. | |
Acceleration Request | ||
Registration Statement on Form S-3 | ||
File No. 333-279274 |
Dear Sir/Madam:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the Securities Act), and in connection with the above-referenced Registration Statement (the Registration Statement), Savara, Inc., a Delaware corporation (the Company), hereby respectfully requests that the U.S. Securities and Exchange Commission (the Commission) declare the Registration Statement effective on Tuesday, May 21, 2024, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.
The Company hereby authorizes Shawn M. Turner, of Holland & Knight LLP, attorney for the Company, to orally modify or withdraw this request for acceleration.
Please provide a copy of the Commissions order declaring the Registration Statement effective to Shawn M. Turner, Holland & Knight LLP, 1801 California Street, Suite 5000, Denver, CO 80202.
If you have any questions regarding this request, please telephone Shawn M. Turner at (303) 974-6645 at the law firm of Holland & Knight LLP.
Very truly yours, |
/s/ Matthew Pauls |
Matthew Pauls |
Chief Executive Officer |
1